Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
January 09, 2024
Child vaccination is one of the most powerful and cost-effective tools to save lives. But just how good is the data that we’re using to track progress on this life-saving intervention? In this piece, we examine trends in the quality of government-produced vaccination data. Our main message is that r...
Blog Post
November 15, 2023
One of the most salient lessons from the pandemic is the need to diversify manufacturing capabilities and bolster supply resilience to avoid a repeat of the slow and inequitable vaccine roll out in African countries. To turn this lesson into action, the Gavi Secretariat is rapidly advancing plans fo...
Blog Post
October 17, 2023
There’s not a lot of low-hanging fruit in global development. On the issues that matter most, from preventing the next pandemic to expanding migration opportunities, and financing climate adaptation, even minor progress tends to require big financial commitments and often faces deep political resist...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 21, 2023
The politics of antimicrobial resistance (AMR) has changed substantially since we launched the first CGD working group on AMR in 2007. There is now much more awareness about the need to act, even if global solutions have not yet been implemented. Countries including the UK, Canada, and Japan have an...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...